We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Cancer Panel to Review Xinlay, Tarceva, Revlimid and Arranon
FDA Cancer Panel to Review Xinlay, Tarceva, Revlimid and Arranon
August 12, 2005
FDA cancer drug experts will take up four high-priority candidates next month, including Abbott Laboratories’ proposed prostate cancer drug Xinlay and OSI Pharmaceutical’s proposed pancreatic cancer indication for Tarceva.